Kymera Therapeutics Announces Pricing of $250 Million Public Offering

Core Viewpoint - Kymera Therapeutics, Inc. has announced a public offering of $250.8 million in common stock and pre-funded warrants to advance its pipeline of oral small molecule degrader medicines for immunological diseases [1][2]. Group 1: Offering Details - Kymera is selling 5,044,500 shares of common stock at a price of $44.00 per share and pre-funded warrants to purchase 655,500 shares at $43.9999 each [1]. - The gross proceeds from the offering are expected to be approximately $250.8 million, before deducting underwriting discounts and commissions [1]. - The underwriters have a 30-day option to purchase up to an additional 855,000 shares at the public offering price [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance Kymera's pipeline of preclinical and clinical degrader programs, as well as for working capital and other general corporate purposes [2]. Group 3: Company Background - Kymera Therapeutics is a clinical-stage biotechnology company focused on targeted protein degradation (TPD) to develop innovative medicines for significant health issues [6]. - The company aims to provide a new generation of effective therapies for patients with immunological diseases [6].